Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4

• Main Authors: Katherine Griffiths (Author), Uli Binder (Author), William McDowell (Author), Rita Tommasi (Author), Mark Frigerio (Author), William G. Darby (Author), Chris G. Hosking (Author), Lionel Renaud (Author), Matthias Machacek (Author), Peter Lloyd (Author), Arne Skerra (Author), Michael Foley (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Single domain antibodies that combine antigen specificity with high tissue penetration are an attractive alternative to conventional antibodies. However, rapid clearance from the bloodstream owing to their small size can be a limitation of therapeutic single domain antibodies. Here, we describe and...